Medicines for Europe

Official Twitter account for Medicines for Europe. Our 5 pillars: #patients #quality #value #sustainability #partnership. IGBA member. RTs not endorsement

[Oliver Varhelyi @OliverVarhelyi]

🇪🇺 patients need timely access to affordable medicines.

Good discussion with @medicinesforEU President Steffen Saltofte on how generics&biosimilars can contribute to a resilient healthcare system.
Keeping manufacturing in 🇪🇺 is key - our policies must work together to support it

[Medicines for Europe @medicinesforEU]

🙌Our Annual Conference has come to a close, with Session 6 wrapping up 2 days of discussions on the strategic role of off-patent medicines across the EU’s health, industrial and environmental priorities. A big thank you to the team, participants, and speakers! See you next year!

[Medicines for Europe @medicinesforEU]

As off-patent medicines account for around 70% of medicines dispensed in the EU, balancing competitiveness with timely and equitable patient access remains a key objective. Session 5 of #MedsforEU26 explored how our sector can build a stronger strategic partnership for patients.

[Medicines for Europe @medicinesforEU]

🛡️Health security starts before a crisis: this was the key message emerging from the panel discussions in Session 4 of #MedsforEU26. We highlighted how essential policy choices are needed to achieve health security, for which our sector is proud to be a strategic partner.

[Medicines for Europe @medicinesforEU]

Day 2 of #MedsforEU26 kicked off with a clear message from our Vice President Elisabeth Stampa: Europe’s pharmaceutical future will be defined by the choices we make today to remain a strategic partner for Europe.

[Medicines for Europe @medicinesforEU]

As Europe advances its environmental and pharmaceutical agenda, it is essential that policies protect both the environment and patient access to essential medicines. Session 3 of #ANNUAL26 highlighted how conflicting policies can create barriers to access.

[Medicines for Europe @medicinesforEU]

In Session 2 of our Annual Conference, we explored the blueprint for industrial resilience and long-term supply security together with Thedoros Tryfon, Vice President of Medicines for Europe, and MEP Nikos Papandreou.

[Medicines for Europe @medicinesforEU]

A high-level interview between the Minister of Health of Greece Adonis Georgiadis and our President Steffen Saltofte opened the series of panels of #MedsforEU26.
We are ready to continue our partnership with Greece also in view of the upcoming Presidency to the Council of the EU.

[Medicines for Europe @medicinesforEU]

Our Annual Conference opened with keynote opening speech from Vice-President of Πανελλήνια Ένωση Φαρμακοβιομηχανίας (ΠΕΦ) - PEF Theodoros Tryfon and high-level remarks from Minister of State Akis Skertsos on behalf of Prime Minister of the Hellenic Republic.

[Medicines for Europe @medicinesforEU]

🤝 Our Legal Affairs Conference came to an end after two days of discussions on the future of Europe’s pharmaceutical and patent framework. The final afternoon sessions focused on the Biotech Act, divisional patents, and changes in the regulatory environment.

[Medicines for Europe @medicinesforEU]

📢 On Day 2 of #LAC26, morning’s discussions focused on recent developments in EU and US competition policies, IP developments and proposals, such as the Biotech Act, as well as a presentation of the new Industry Report on the SPC Waiver and its strategic relevance.

[Medicines for Europe @medicinesforEU]

🙌 Celebrating its 20th anniversary, our Legal Affairs Conference #LAC26 came back, bringing together leading European legal experts to reflect on two decades of developments in pharmaceutical patent law and policy, while looking ahead to the challenges and opportunities.

[Medicines for Europe @medicinesforEU]

🙌 Celebrating its 20th anniversary this year, our Legal Affairs Conference #LAC26 is back, bringing together leading European legal experts to reflect on two decades of developments in pharmaceutical patent law and policy, while looking ahead at key challenges and opportunities.

[Medicines for Europe @medicinesforEU]

What role can Europe play in supporting the strategic off-patent medicines sector during uncertain geopolitical times? Register to our Annual Conference to explore current trade opportunities to drive job growth, competitiveness and supply resilience:
➡️ https://t.co/IogGmTy3wp

[Medicines for Europe @medicinesforEU]

Last week, we took part in the @REMEDi4ALL #iDR26, focused on accelerating real-world change in medicines repurposing. We brought the perspective of the off-patent sector, especially on unlocking the full potential of value added medicines to improve patient access and outcomes.

[Medicines for Europe @medicinesforEU]

What role do we play in building more resilient and secure healthcare systems across Europe?
Come and explore at our Annual Conference #MedsforEU26 how our sector represents a strategic partner for health security.
➡️ Register here: https://t.co/IogGmTy3wp

[Medicines for Europe @medicinesforEU]

🗺️ Session 6 of #BIOS26 highlighted how global acceptance and use of biosimilar medicines continue to grow across regions, as regulatory agencies work to further unlock their full potential through a range of initiatives and measures.

[Medicines for Europe @medicinesforEU]

🌐 AI is increasingly reshaping how medicines are developed and manufactured, including in the biosimilar space, with the goal of advancing patient care and supporting public health.
Spotlight 3 of #BIOS26 explored how the EMA is addressing these changes.

[Medicines for Europe @medicinesforEU]

📑 Global regulators are actively embedding the latest scientific advancements into biosimilar regulatory guidance.
Session 5 of #BIOS26 explored this latest evolution in biosimilar development.

[Medicines for Europe @medicinesforEU]

🧪 How are our healthcare systems keeping pace with the biosimilar opportunity?
Session 4 of #BIOS26 focused on rethinking care pathways in the biosimilar era, offering a multi-stakeholder perspective on the importance of bridging policy intention and action.